ARCHIVES

In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office

This article is from The Cancer Letter archive.

Vol. 18 No. 45 | November 20, 1992

Download PDF Visit The Full Archive

Related Articles

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

Dramatic Increase In Third World Cancer Rates May Face National, International Organizations: Murphy

September 17, 1982

Zevalin Regimen Effective In Mantle Cell Lymphoma

January 30, 2004

Gregory Reaman Elected Chairman, C.O.G.; NCI Seeks Nominations For Consumer Group. “We Need A Long-Term Commitment” To Discovery.

December 15, 2000

NCI, FDA Near Agreement On INDs; Young, Hoogstraten Clash On Rubidazone

January 14, 1977

New Cyclotron Delivered To University of Maryland, Instigating D.C.-Area Proton Radiation Competition

June 20, 2014